AstraZeneca faces more Covid-19 vaccine questions after manufacturing error


 

AstraZeneca Plc and the University of Oxford face mounting questions about their Covid-19 vaccine trial results after acknowledging a manufacturing error.

While an announcement earlier this week by Astra and Oxford showed their shot was 70 per cent effective on average in a late-stage study, the scant details released by the UK partners have sparked worries, with some expressing doubts about whether US regulators would clear it.

Astra and Oxford had said their vaccine was 90 per cent effective when a half-dose was given before a full-dose booster. Two full doses showed an efficacy of 62 per cent. But the head of the US vaccine program known as Operation Warp Speed said the next day that the dose showing the higher level of effectiveness was tested in a younger population. Read More

Comments

Popular posts from this blog

Invest in smallcase with sebi registered professionals

Teji Mandi Your Ultimate Share Market App for Informed Investing

Unleashing the Potential of Stocks: Crafting a Successful Stock Portfolio